All Search Results
News Releases
Jul 18, 2026, 14:55 ET REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
retinal laser; surgical treatment may be required for advanced PDR.2 ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jul 17, 2026, 10:15 ET Bioinformatics Market worth $34.41 billion by 2031 - Exclusive Report by MarketsandMarkets™
multi-omics data integration solutions.Pharmaceutical & biotechnology companies held largest share of bioinformatics market in 2025By end user, the bioinformatics market is divided into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinical
More news about: MarketsandMarkets
Jul 17, 2026, 07:00 ET REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
registration or qualification under the applicable securities laws of such state or jurisdiction.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jul 17, 2026, 06:40 ET Medical Plastics Tubing Market worth $6.81 billion by 2031 - Exclusive Report by MarketsandMarkets™
and disposable as a measure to reduce the risk of infection. Both these aspects play a role in the overall market growth. The pharmaceutical and biotechnology industries are increasing their R&D activities and investments in advanced drug delivery technologies, which would further drive this segment.Inquiry
More news about: MarketsandMarkets
Jul 16, 2026, 23:48 ET HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise that enrolment has been completed in Regimen
More news about: Neurizon Therapeutics Limited
Organizations
Resources
News Trends
The Tripledemic, Disease Awareness and More Health News Trends
dinner. Luckily, she made a full recovery! Big news in healthcare acquisitions came in December when the biotechnology company Amgen